Graves' ophthalmopathy appears to be an organspecific autoimmune disorder.' A still unidentified pathogenic process induces swelling, lymphocytic infiltration, and later fibrosis and contractures that restrict *the normal function of the extraocular muscles.' Two stages in the development of the disease are generally distinguished: the stage of active inflammation in which the eyes are red and painful, and the quiescent stage in which the eyes are white and unchanging with a painless motility deficit. ' Treatment of serious Graves' ophthalmopathy may be either non-surgical or surgical. Of the nonsurgical treatments orally administered steroids or radiotherapy or a combination of both are usually favoured. No agreement on the results of these treatments can be found. Brain4 reported immediate beneficial effects on the inflammatory components of the ophthalmopathy after short high doses of corticosteroids. Day For each of the signs present one point is given. The sum of these points defines the activeits score. symptoms to disappear after anti-inflammatory treatment. We therefore consider these kinds of pain to be directly related to the inflammation in the orbit and thus useful in assessing inflammatory activity. They differ from pain caused by corneal defects, pain due to a spasm of the orbicularis muscle secondary to photophobia, or pain in the context of asthenopia because of a changed refraction. We consider these last symptoms to be epiphenomena and therefore not useful in assessing the disease activity.
Redness as an expression of inflammation is caused by vasodilatation. In Graves' ophthalmopathy this is seen as redness of the eyelids and over the conjunctiva (Fig. 1 ). These signs must be differentiated from the redness accompanying exposure keratitis and the grossly dilated vessels over the insertions of the extraocular muscles. The latter condition is seen both in active and in quiescent Graves' ophthalmopathy.
Swelling in Graves' ophthalmopathy is seen as chemosis (oedema of the conjunctiva) and a swollen caruncule (Fig. 2) . Both eyelids can be caused by oedema, fat prolapse through the orbital septum, or fibrotic degeneration (Fig. 3) . Here only eyelid oedema should be considered a sign of inflammation. To differentiate oedema from other causes of eyelid swelling palpation and illumination of the eyelids with a torch are mandatory.
In Graves' ophthalmopathy inflammation causes fluid accumulation and cellular infiltration in the orbit, later to be followed by fibrotic tissue. Proptosis and swelling of the eyelids are the result of the entire process. Therefore proptosis and eyelid swelling are not in themselves signs of acute inflammation. However, increasing proptosis in this context is a proof of it. A test-retest error of 2 mm is usually cited as the limit of exophthalmometer accuracy."' We therefore consider an increase in proptosis of 2 or more millimetres to be a positive sign of disease activity.
Visual impairment in Graves' ophthalmopathy, resulting from dysfunction of the optic nerve, is caused by raised intraorbital pressure due to the inflammatory process.'2 Therefore a decrease of visual acuity as a result of optic compression is a sign of disease activity. However, a decrease of visual acuity due to corneal defects cannot be considered an early sign of active Graves To detect an increase in proptosis or a decrease in eye movements or visual acuity over a span of time at least two different consecutive examinations are necessary. In view of the natural history of Graves' ophthalmopathy we consider that the interval between these examinations should be at least one and not more than three months.
Pilot study to test efficacy of classification
The patients' records from an ongoing prospective, randomised, clinical trial to compare the efficacy, safety, and tolerability of cyclosporin and oral prednisone in severe Graves' ophthalmopathy'4 were used for this purpose. In this study 26 consecutive patients with serious Graves' ophthalmopathy, defined as falling into NOSPECS categories 2c, 3b, 3c, 4b, 4c, 5a, 5b, 5c, or 6a, were treated with oral prednisone or cyclosporin for a period of 12 weeks. These patients were euthyroid for more than two months when they started the trial. They had had no previous eye treatment other than local measures. Eighteen were female and eight male. Their ages ranged from 23 to 70 years.
The treatment consisted of 60 mg prednisone/day during the first two weeks, 40 mg during the next two weeks, 30 mg during the next four weeks, and 20 mg during the last four weeks, then tapering off, or cyclosporin 7-5 mg/kg bodyweight/day for 12 weeks. When the therapeutic outcome after 12 weeks was considered unsuccessful, the patients were treated for another 12 weeks with a combination of both oral prednisone (20 mg/day) and cyclosporin (in the same dosage as mentioned above). After 24 weeks the final outcome was evaluated. The success or failure of treatment was defined as shown in Table 2 . Patients were examined before and at the beginning of therapy and after 1, 3, 4, and 6 months. Apart from classifying each patient in the NOSPECS system in each category, the visual acuity, proptosis, and eye movements were measured and eyelid oedema and chemosis recorded. At each visit photographs of the face were taken and the patients were asked about their complaints. Coronal CT scans of the orbits were carried out at the beginning of treatment.
The definitions of pain, as given in our scoring classification, could not be applied, as we were using Fig. 4) . Three patients showed a worsening of their ophthalmopathy during treatment. They had an activity score of 1 or 2 points. The condition of the remaining three patients, all of them with an activity score of zero, did not change.
The degree of extraocular muscle enlargement on the orbital coronal CT scan was assessed in a rating system of 5 points (0: no enlarged muscles; 5: grossly enlarged muscles) by an ophthalmologist who was not informed about the activity score. By linear correlation and regression analysis a significant correlation was found between the extraocular muscle size and our activity score (r=(052, volume= 1-9+0n31xactivity score, p= 0007). The relationships between muscle size and the activity score will be studied in more detail in future prospective studies. Fig. 4 suggests that the clinical activity score is 
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